Printer Friendly

ENDOTRONICS HOLDS ANNUAL MEETING OF SHAREHOLDERS: UPDATES INVESTMENT COMMUNITY ON ACUMOUSE AND ARTIFICIAL LIVER PROGRAM

 ENDOTRONICS HOLDS ANNUAL MEETING OF SHAREHOLDERS:


UPDATES INVESTMENT COMMUNITY ON ACUMOUSE AND ARTIFICIAL LIVER PROGRAM
 MINNEAPOLIS, March 5 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) held its Annual Meeting of Shareholders on Feb. 27. Addressing shareholders, employees and investment professionals that attended, Chairman Eugene Schuster said: "The achievements of this past year and the promise evident in our future wouldn't be possible without our highly dedicated work force and management team. I can't stress to you strongly enough that Endotronics is positioned to capitalize on its many assets as it moves further into the 1990s."
 Richard E. Sakowicz, president of Endotronics, Inc., commented: "The highlights of the year are many. They include the introduction of a new research scale instrument called the ACUMOUSE(TM). This revolutionary tool for biotechnology research is designed to replace laboratory mice as a source of monoclonal antibodies, which are used for a variety of applications including research into treatments for cancer, AIDS, hepatitis and other diseases. Shipment of the ACUMOUSE is expected to begin in the spring of 1992. We have also begun our collaboration with the University of Minnesota to develop an external device that will function as an artificial liver. This device would be utilized in hospital intensive care units to temporarily replace the liver function in patients who suffer from acute liver injury and need temporary support or those with irreversible injury needing liver support until transplantation."
 During the formal portion of the meeting, a board of six directors was elected to serve until the next annual meeting, the proposal to amend the company's Articles of Incorporation to increase its authorized common stock was ratified, and the Endotronics, Inc. 1992 Stock Option Plan was adopted.
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide. The company is a recognized leader in hollow fiber cell culture instrumentation with more than 675 instruments installed worldwide.
 -0- 3/5/92
 /CONTACT: Yvonne L. Marschner-Bova of Endotronics, 313-871-7350/
 (ENDO) CO: Endotronics, Inc. ST: Minnesota IN: MTC SU:


SB -- DE012 -- 5393 03/05/92 11:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:355
Previous Article:ENTERGY CORPORATION DECLARES QUARTERLY DIVIDEND, CONTINUES STOCK REPURCHASE PROGRAM
Next Article:LISA HENSON NAMED EXECUTIVE VICE PRESIDENT, WARNER BROS. THEATRICAL PRODUCTION
Topics:


Related Articles
ENDOTRONICS, INC. SIGNS AGREEMENT WITH GOODWIN INSTITUTE FOR CANCER RESEARCH INC. TO EXPAND CONTRACT PRODUCTION SERVICES
ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND
ENDOTRONICS, INC. REPORTS SECOND-QUARTER AND SIX-MONTHS RESULTS
ENDOTRONICS, INC. AND WHEATON SCIENCE PRODUCTS, INC. ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT
ENDOTRONICS, INC. SIGNS STRATEGIC COOPERATION AGREEMENT WITH TECNOMARA AG OF SWITZERLAND
ENDOTRONICS REPORTS FOURTH-QUARTER AND FISCAL 1992 YEAR-END RESULTS
ENDOTRONICS, INC. UPGRADES PRODUCTION FACILITY AND SIGNS CYTOGEN CORPORATION CONTRACT
ENDOTRONICS REPORTS RESULTS FOR ITS FIRST QUARTER ENDED DEC. 31, 1992

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters